Abstract
The creating of the reactivators of Cholinesterase (ChE) activity is an example for a direct synthesis of biochemical antidotes. The major oximes such as 2PAM, 2PAS, TMB-4 and toxogonin are being applied on a wide range and have been examined in detail. The difficulty in reactivation of the ChE activity and slight antidote effect concerning intoxication with some organophosphorus compounds (OPC), are some of the reasons for continuing the examinations for the creation of new reactivators of ChE. The creation of the so called “H “ oximes gives a new stimulus in this direction. During the evaluation of the new compounds in addition to the antidotal effects and the reactivating effect according to the inhibition of ChE by different OPC, we should examine the recovery of the blocked neuromuscular transmission, the cholinergic receptor functions, the anticonvulsive activity after intoxication with OPC. We consider the importance of the evaluation of pharmacokinetics of the reactivators as well as changes on background of intoxications with different kinds of OPC, as well as of the toxicokinetics of OPC after treatment. It is important that before the synthesis of some new compounds, to examine the QSAR not only considering the reactivation of ChE, but also having in mind their ability to reverse neuromuscular blockade.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Briggs, C. and Simons, K. (1984) Personal protection against chemical agents; development of antidotal treatment for organophosphorous poisoning, Arch. Belg. Med. Sol. Hyg. Med. Tran. Med. Lec. XX, pp. 260–273.
Cassel, G., Waara, L. and Goranson-Nyberg, A. (1996) Pharmacokinetic of HI-6 in Blood and in Extracellulare space in Brain, Med. Def. Biosc. Rev., May 12–18, Baltimore, USA.
Clement, J., Shiloff, J. and Gennings, C. (1987) A combination of ChE reactivators, HI-6 and obidoxime, against tabun and soman poisoning of mice, Arch. Toxicol. 61, 70–75.
Dishovsky, C. (1971) PhD work, Kiev.
Dishovsky, C. (1990) Reactivators of ChE, Selskostop. Academia, Sofia
Dishovsky, C., Draganov, D. and Samnaliev, I. (1996) Study on HGG-and BDB-oximes in reversal of neuromuscular block produced by an organophosphate, Medic. Defence Biosc. Rev., Proc. VI, 147–153.
Dishovsky, C. and Draganov, D. (1996) Pharmacokinetics of HI-6 in cats, Proceedings of CB Med. Tr. Symp. Spiez, Switzerland, 9–13.
Eyer, P., Hagedorn, I., Klimek, R., Lipstren, P., Loffler, M., Oldiges, H., Spointer, U., Steidl, I., Szinicz, L. and Worek, T. (1993) Arch. Toxicol. 66, 603–621.
Maximovic, M., Pantelic, D., Kovacevic, V. and Binenfeld, Z. (1987) Protective effects of HI-6 and Toxogonine combination in soman and tabun poisoned rats, Acta Pharmac. Jugosl. 37,227–229.
Wilson, J. (1951) Acetylcholinesterase, J. Biol. Chem. 190, 111–123.
Wolthuis. O., Benshop H. and Berends, F. (1981) Persistence of the anti-choliesterase soman in rats; antagonism with a non-toxic simulator of this organophosphate. Eur. J. Pharmac. 69, 379–383.
Worek, F., Widmann, R., Littig, P., Heyes, G., Grencner, L., Zollich, H. and Szinich, L. (1998) Choice of Oxime for treatment of Poisoning by Different Organophosphorus Compounds, The ASA Newsletter, 1, 16–18.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Dishovsky, C.D. (1999). Reactivators, from Classic to a New Generation. In: Sohns, T., et al. NBC Risks Current Capabilities and Future Perspectives for Protection. NATO Science Series, vol 25. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4641-8_14
Download citation
DOI: https://doi.org/10.1007/978-94-011-4641-8_14
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5803-9
Online ISBN: 978-94-011-4641-8
eBook Packages: Springer Book Archive